Esperion Reports First Quarter 2024 Financial Results : vima

– Q1 Total Revenue Grew 467% Y/Y to $137.7 Million, Reflecting Strong Growth Globally – – Q1 U.S. Net Product Revenue Grew 46% Y/Y to $24.8 Million – – Q1 Retail Prescription Equivalents...

Related Keywords

Netherlands , Thailand , Japan , Czech Republic , Tiffany Aldrich , Daiichi Sankyo Europe , Sheldon Koenig , Esperion Therapeutics Inc , European Commission Decision For Expanded Labels , National Health Insurance , Exchange Commission , European Commission , European Medical Agency , Daiichi Sankyo Company , Committee For Medical Products Human Use , Revenue Grew , Reflecting Strong Growth Globally , Product Revenue Grew , Prescription Equivalents Grew , Increased Momentum , Label Expansions Expected Throughout , Broad New Label Expansions , Prevent Heart Attacks , Reduce Cardiovascular Risk , Secondary Prevention Patients , Received Positive Opinion , Medical Products , Human Use , European Commission Decision , Expanded Labels Anticipated , Conference Call , Webcast Today , Lipid Lurker , Sankyo Company , Japan New Drug Application , Esperion Therapeutics , Adverse Event , Prescribing Information , Contact Information , Markets ,